Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Deutsche Bank upgraded Cisco (CSCO) to Buy from Hold with a price target of $73, up from $65. The firm sees improved visibility towards “durable” mid-single-digit growth in upcoming years for Cisco, with tailwinds from artificial intelligence, a Campus portfolio refresh, more favorable near-term competitive dynamics in Networking and improved scale in Security.
• TD Cowen upgraded Celsius Holdings (CELH) to Buy from Hold with a price target of $55, up from $37. The firm expects to see continued improvement through the summer as Celsius’ comparable sales ease from 35% in May to 19% in June and 11% in July.
• Stifel upgraded Incyte (INCY) to Buy from Hold with a price target of $107, up from $75. This weekend’s presentation of preliminary INCA033989 dose-escalation data in essential thrombocythemia patients “represents a best-case scenario,” the firm tells investors in a research note.
• Wells Fargo upgraded Celanese (CE) to Overweight from Equal Weight with a price target of $66, up from $45. The firm sees potential for sequential earnings improvement on cost savings and reduced maintenance and notes its outlook assumes no demand improvement near term.
• Wells Fargo upgraded Wix.com (WIX) to Overweight from Equal Weight with a price target of $216, up from $173. The firm says its “strong” partner channel checks leave it confident Wix can take price in fiscal 2026 and raise bookings by 2%.

Top 5 Downgrades:

• BofA downgraded CoreWeave (CRWV) to Neutral from Buy with a price target of $185, up from $76. Noting that the stock has run up 145% following Q1 results, the firm says it believes much of the near-term upside has been priced in.
• H.C. Wainwright downgraded Sarepta (SRPT) to Sell from Neutral with a $10 price target. The company announced another death due to acute liver failure in a second non-ambulatory Duchenne muscular dystrophy patient treated with Elevidys, and is suspending shipments of the drug to non-ambulatory DMD patients until an immunosuppressive regimen can be agreed upon with regulators and implemented, the firm tells investors in a research note. Piper Sandler also downgraded Sarepta to Neutral from Overweight with a price target of $36, down from $70.
• Baird downgraded Pros Holdings (PRO) to Neutral from Outperform with a price target of $18, down from $27. The firm says that given recent internal changes at the company, it is “increasingly concerned” about Pros’ ability to execute its long-term targets.
• Jefferies downgraded Packaging Corp. (PKG) to Hold from Buy with a price target of $205, down from $245. The firm still views Packaging Corp. as best in class, but sees the company’s competitive edge flattening and the stock limited by its premium valuation.
• Citizens JMP downgraded Angi Inc. (ANGI) to Market Perform from Outperform without a price target following a transfer of coverage. The several strategic changes underway have the potential to improve the core fundamentals of Angi’s marketplace, but competition among digital home improvement and maintenance marketplaces has intensified, the firm says.

Top 5 Initiations:

• Barclays initiated coverage of Hinge Health (HNGE) with an Overweight rating and $43 price target. Musculoskeletal issues are expensive, and Hinge can “bend the cost curve” with digital physical therapy, the firm says. KeyBanc, Morgan Stanley, RBC Capital, Stifel, Truist, Evercore ISI, William Blair, Hinge Health, BofA, Canaccord, and Piper Sandler started coverage of the stock with Buy-equivalent ratings.
• Citizens JMP initiated coverage of MNTN (MNTN) with an Outperform rating and $23 price target. The firm’s positive view is based on MNTN’s ability to attract small businesses and retain and grow their advertising budgets. Evercore ISI, Raymond James, Susquehanna, Loop Capital, and Needham also started coverage of the stock with Buy-equivalent ratings, while Citi and Morgan Stanley initiated the name with Neutral-equivalent ratings.
• Leerink initiated coverage of Medtronic (MDT) with an Outperform rating and $110 price target. The firm sees a positive “shifting tide” for Medtronic driven by the company’s Cardiac Ablation Solutions business offering a significant and underappreciated source of upside, its recently announced decision to separate its Diabetes business, the company’s portfolio having relatively significant exposure to several other high-growth end-markets, and a clear shift in Medtronic’s M&A strategy that could help bolster its longer-term growth portfolio. Leerink also started coverage of Boston Scientific (BSX) with an Outperform rating and $118 price target.
• Truist initiated coverage of Insulet (PODD) with a Buy rating and $365 price target. Truist expects Insulet’s Omnipod 5 will remain the only true tubeless and fully disposable patch pump for the foreseeable future, which should allow Insulet to maintain a market leadership patch pump position within the growing Type 1 and Type 2 diabetes markets even if/when competitor patch designs begin coming to market over the next few years. The firm also started coverage of DexCom (DXCM) with a Buy and Tandem Diabetes (TNDM) with a Hold rating.
• UBS initiated coverage of Freshpet (FRPT) with a Sell rating and $65 price target. The firm says consensus estimates for Freshpet are too high, and that “more subdued” growth in the near-term should cause the stock’s valuation to contract further.